Clareo Health | An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Reports meeting migraine diagnostic criteria consistent with International Classification of Headache Disorders (ICHD) (i.e., they report symptoms accompanying their headaches that meet migraine criteria22 at screening).
Currently using ubrogepant for acute treatment of migraine.
Experienced at least 3 migraine attacks in the last 30 days.
Currently taking atogepant for preventive treatment of migraine and has been taking atogepant, at the same dose, for at least 30 days.
You may not be if
Report currently taking Rimegepant (Nurtec®) for migraine treatment (acute or preventive).
Report currently taking any of the anti-CGRP mAbs for preventive treatment of migraine:
